Subscribe
epilepsy-istock-636332090-sudok1-
sudok1 / iStockphoto.com
27 March 2017Americas

PTAB upholds anti-epileptic drug patent

The Patent Trial and Appeal Board (PTAB) has upheld a Research Corporation Technologies patent for anti-epileptic drug Vimpat (lacosamide) in a case brought by Argentum Pharmaceuticals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Fed Circuit rules against Mylan in patent dispute over epilepsy drug
4 February 2019   Generic-drug manufacturers Mylan Pharmaceuticals, Breckenridge Pharmaceutical and Alembin Pharmaceuticals have lost their bid to prove that claims in a patent owned by US company Research Corporation Technologies, were invalid on the grounds of obviousness.


Editor's picks

Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025

Editor's picks

Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025
Americas
LSPN finalists revealed for first-ever US awards
3 March 2025
Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025

More on this story

Americas
Fed Circuit rules against Mylan in patent dispute over epilepsy drug
4 February 2019   Generic-drug manufacturers Mylan Pharmaceuticals, Breckenridge Pharmaceutical and Alembin Pharmaceuticals have lost their bid to prove that claims in a patent owned by US company Research Corporation Technologies, were invalid on the grounds of obviousness.

More on this story

Americas
Fed Circuit rules against Mylan in patent dispute over epilepsy drug
4 February 2019   Generic-drug manufacturers Mylan Pharmaceuticals, Breckenridge Pharmaceutical and Alembin Pharmaceuticals have lost their bid to prove that claims in a patent owned by US company Research Corporation Technologies, were invalid on the grounds of obviousness.

More features

European court upholds 10x patent after Nanostring appealed injunction
Takeda, Pfizer, and Sumitomo sue to protect $379m Orgovyx revenue
Verily, IBM, litigation funder on the art of leveraging patents
Tempus sues competitor over AI cancer diagnostic tech
Trouble at the USPTO—Part II: Bracing for impact
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
Trump chooses crypto-focused litigation funding expert to lead USPTO
Novo Nordisk strikes again over Wegovy generic